Rubius Therapeutics, Inc. (RUBY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7581 |
| Open | 0.7805 |
| Bid | 0.7627 x 800 |
| Ask | 0.8070 x 1200 |
| Day's Range | 0.7501 - 0.8149 |
| 52 Week Range | 0.6500 - 24.8400 |
| Volume | |
| Avg. Volume | 765,304 |
| Market Cap | 71.884M |
| Beta (5Y Monthly) | 2.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1 Arm of RTX-240 + Pembrolizumab in Advanced Solid Tumors and Expansion Cohorts in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Dose Escalation Continues in Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date; Initial
- GlobeNewswire
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction
- PR Newswire
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas.
